TSRL announces formation of Scientific Advisory Board

 

Ann Arbor, MI (April 13, 2009) – Therapeutic Systems Laboratory (TSRL, Inc.), a biopharmaceutical company developing oral drug delivery solutions for poorly absorbed drug candidates, welcomes Drs Andreas Bommarius, Shan Lu, and Blake Roessler, to their Scientific Advisory Board (SAB).

Dr. Bommarius' area of expertise is in biomolecular engineering, especially biocatalysis, bioprocessing, and protein stability. Dr. Bommarius joined the Georgia Tech faculty in 2000 after an industrial career of more than 10 years with the Degussa Company in specialty chemicals where he headed the Biocatalysis laboratory and pilot plant. At Georgia Tech, he is a faculty member of both the School of Chemical and Biomolecular Engineering and the School of Chemistry and Biochemistry. Andy brings a strong formulation manufacturing perspective to TSRL’s research and will advise us on scale-up and manufacturing issues of our product candidates.

Dr. Shan Lu is a researcher and clinician at the University of Massachusetts’s Medical School. Shan focuses on translational research in vaccine development both for civilian and biodefense related targets. With his extensive experience in developing clinical development trial protocols, he was able to move a candidate human HIV vaccine from early preclinical stage to human testing within 3.5 years. Shan is a pioneer in DNA vaccine delivery and has worked on a wide range of anti-infective vaccine and drug candidates. In addition, Shan founded Antibody Science, Inc., a start-up firm focused on novel antibody development. Shan’s clinical perspective in antiviral drug development paired with his unique knowledge of the biodefense space will help shape TSRL’s development strategies.

Dr. Blake Roessler is Associate Professor of Internal Medicine in the Division of Rheumatology at the University of Michigan Medical School. Dr. Roessler leads active basic and clinical research programs and continues as a practicing clinician. He currently directs the Viral Vector Core, the Process Development Core and the Human Applications Laboratory Core. Dr. Roessler has a long-standing research interest in nucleic acid delivery technologies and is co-inventor of the BAC technologies. Blake's broad clinical and gene therapy background make him an ideal advisor to TSRL's continued strategic interest in peptide and biologics delivery.

Therapeutic Systems Research Laboratories (TSRL), Inc. is a privately held oral drug delivery specialty firm focused on R&D efforts to enhance the oral absorption of investigational and marketed compounds currently not suitable for this most convenient route of drug administration. TSRL is applying its technologies towards the discovery and development of oral therapies for infectious diseases, osteoporosis and gastrointestinal disorders. More detailed information about TSRL is available at the company website www.tsrlinc.com or by contacting Dr. Elke Lipka, Vice President for Business Development, 734 663-4233 x236, elipka@tsrlinc.com